These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 34102344

  • 1. Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
    Francis JH, Canestraro J, Haggag-Lindgren D, Harding JJ, Diamond EL, Drilon A, Li BT, Iyer G, Schram AM, Abramson DH.
    Ophthalmol Retina; 2021 Dec; 5(12):1187-1195. PubMed ID: 34102344
    [Abstract] [Full Text] [Related]

  • 2. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
    Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F.
    Ophthalmology; 2017 Dec; 124(12):1788-1798. PubMed ID: 28709702
    [Abstract] [Full Text] [Related]

  • 3. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.
    Weber ML, Liang MC, Flaherty KT, Heier JS.
    JAMA Ophthalmol; 2016 Aug 01; 134(8):855-62. PubMed ID: 27309887
    [Abstract] [Full Text] [Related]

  • 4. Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
    Francis JH, Harding JJ, Schram AM, Canestraro J, Haggag-Lindgren D, Heinemann M, Kriplani A, Jhaveri K, Voss MH, Bajorin D, Abou-Alfa GK, Iyer G, Drilon A, Rosenberg J, Abramson DH.
    JAMA Ophthalmol; 2021 Oct 01; 139(10):1126-1130. PubMed ID: 34473206
    [Abstract] [Full Text] [Related]

  • 5. Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
    van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ.
    Ophthalmology; 2015 Sep 01; 122(9):1907-16. PubMed ID: 26123090
    [Abstract] [Full Text] [Related]

  • 6. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC, Dijkman G, Boon CJF.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct 01; 255(10):2029-2035. PubMed ID: 28674835
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, Kneba M, Grzybowski A.
    BMC Ophthalmol; 2019 Jul 25; 19(1):160. PubMed ID: 31345183
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ, Comparison of Age-related Macular Degeneration Treatments Trials Research Group.
    Ophthalmology; 2016 Apr 25; 123(4):865-75. PubMed ID: 26783095
    [Abstract] [Full Text] [Related]

  • 13. Fundus autofluorescence findings in central serous chorioretinopathy using two different confocal scanning laser ophthalmoscopes: correlation with functional and structural status.
    Shin JY, Choi HJ, Lee J, Choi M, Chung B, Byeon SH.
    Graefes Arch Clin Exp Ophthalmol; 2016 Aug 25; 254(8):1537-1544. PubMed ID: 26690973
    [Abstract] [Full Text] [Related]

  • 14. Retinoschisis in eyes with pachychoroid and retinal pigment epithelial atrophy.
    Baek J, Lee JH, Lee WK.
    Graefes Arch Clin Exp Ophthalmol; 2019 Sep 25; 257(9):1863-1871. PubMed ID: 31222406
    [Abstract] [Full Text] [Related]

  • 15. BASELINE SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AS A PREDICTOR OF VISUAL OUTCOME AND RECURRENCE FOR CENTRAL SEROUS CHORIORETINOPATHY.
    Lee H, Lee J, Chung H, Kim HC.
    Retina; 2016 Jul 25; 36(7):1372-80. PubMed ID: 26702841
    [Abstract] [Full Text] [Related]

  • 16. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B, Fischer F, Ehlken C, Bühler A, Stahl A, Schlunck G, Böhringer D, Agostini H, Lange C.
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov 25; 254(11):2151-2157. PubMed ID: 27145785
    [Abstract] [Full Text] [Related]

  • 17. FUNDUS AUTOFLUORESCENCE LIFETIMES AND CENTRAL SEROUS CHORIORETINOPATHY.
    Dysli C, Berger L, Wolf S, Zinkernagel MS.
    Retina; 2017 Nov 25; 37(11):2151-2161. PubMed ID: 28099314
    [Abstract] [Full Text] [Related]

  • 18. Central serous chorioretinopathy in elderly subjects: angiographic and tomographic characteristics.
    Bae K, Nam SW, Kang SW, Kim ES, Yu SY, Kim KT, Kim SJ.
    Graefes Arch Clin Exp Ophthalmol; 2019 Feb 25; 257(2):279-288. PubMed ID: 30564905
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M.
    Int Ophthalmol; 2017 Jun 25; 37(3):483-489. PubMed ID: 27392913
    [Abstract] [Full Text] [Related]

  • 20. [Pathophysiology of macular diseases--morphology and function].
    Iida T.
    Nippon Ganka Gakkai Zasshi; 2011 Mar 25; 115(3):238-74; discussion 275. PubMed ID: 21476310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.